Options for intravenous iron supplementation in hemodialysis patients

다국어 초록 (Multilingual Abstract)

Anemia is one of the most prevalent disorders in patients receiving hemodialysis (HD) treatment. The key pathophysiology of anemia in HD patients is decreased production of erythropoietin; regular hormonal replacement with erythropoiesis-stimulating agents (ESAs) plays central role in anemia treatment. The use of ESAs has yielded several beneficial effects, including improved quality of life, reduced need for blood transfusions and decreased anemia-related morbidity and mortality in chronic kidney disease (CKD). However, epoetin-α treatment with a target hemoglobin over 13.5 g/dL was associated with increased risk of death and hospitalization for congestive heart failure and no additional benefit compared with a target hemoglobin of 11.3 g/dL [1]

참고문헌 (Reference)

1 Hofman JMG, "Switching iron sucrose to ferric carboxymaltose associates to bet-ter control of iron status in hemodialysis patients" 19 : 242-, 2018

2 Vaziri ND, "New options for iron supplementation in maintenance hemodialysis patients" 67 : 367-375, 2016

3 Macdougall IC, "Intravenous iron in patients undergoing maintenance hemodialysis" 380 : 447-458, 2019

4 Charytan C, "Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease : a randomized, active-controlled, multi-center study" 28 : 953-964, 2013

5 Antonio Lacquanit, "Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: reduction of erythropoietin dose in 4 years of follow-up" 대한신장학회 39 (39): 334-343, 2020

6 Onken JE, "Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function : the REPAIR-IDA trial" 29 : 833-842, 2014

7 Macdougall IC, "FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia" 29 : 2075-2084, 2014

8 Singh AK, "Correction of anemia with epoetin alfa in chronic kidney disease" 355 : 2085-2098, 2006

9 Pfeffer MA, "A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease" 361 : 2019-2032, 2009

10 Qunibi WY, "A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients" 26 : 1599-1607, 2011